Edition:
India

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

9.10USD
22 Jun 2018
Change (% chg)

$0.20 (+2.25%)
Prev Close
$8.90
Open
$8.95
Day's High
$9.20
Day's Low
$8.95
Volume
8,548
Avg. Vol
19,666
52-wk High
$13.10
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Juniper Pharmaceuticals Reports Q1 Earnings Per Share Of $0.06
Thursday, 10 May 2018 

May 10 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q1 EARNINGS PER SHARE $0.06.Q1 REVENUE $15.5 MILLION.JUNIPER PHARMACEUTICALS - "ENGAGEMENT WITH ROTHSCHILD TO PURSUE STRATEGIC ALTERNATIVES IS PROGRESSING".  Full Article

Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY.JUNIPER PHARMACEUTICALS INC - ‍EXTENSION OF SUPPLY AGREEMENT FOR CRINONE WITH AFFILIATE OF MERCK KGAA.JUNIPER PHARMACEUTICALS INC - ‍AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024​.  Full Article

Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
Wednesday, 3 Jan 2018 

Jan 2 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS.JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018.JUNIPER PHARMACEUTICALS INC - CONTINUED "STRONG" DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018.JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING.JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER.JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH.  Full Article

Juniper Pharmaceuticals reports third quarter results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Juniper Pharmaceuticals Inc :Juniper Pharmaceuticals reports third quarter 2017 financial and operating results.Q3 loss per share $0.13.Q3 revenue rose 12 percent to $13 million.  Full Article

Juniper Pharmaceuticals Q2 loss per share $0.16
Thursday, 4 Aug 2016 

Juniper Pharmaceuticals Inc : Juniper Pharmaceuticals reports second quarter 2016 financial results . Q2 revenue $11.9 million . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.16 . Q2 revenue view $9.5 million -- Thomson Reuters I/B/E/S . Anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 result .Now anticipates full-year 2016 revenue growth in low- to mid-teen percentage range over 2015 results.  Full Article

Juniper Pharmaceuticals appoints CEO
Wednesday, 20 Jul 2016 

Juniper Pharmaceuticals Inc : Secor will also be appointed to board of directors . Juniper Pharmaceuticals appoints Alicia Secor president and chief executive officer . Secor will also be appointed to board of directors .Secor succeeds Frank Condella, who announced his intent to retire as Juniper's president and CEO earlier this year..  Full Article

Juniper Pharmaceuticals completes enrollment in phase 2b clinical trial of COl-1077, 10 pct lidocaine vaginal gel
Thursday, 7 Jul 2016 

Juniper Pharmaceuticals Inc : Juniper pharmaceuticals announces completion of enrollment in phase 2b clinical trial of col-1077 10% lidocaine vaginal gel for gynecologic procedure pain .Remains on track to report top-line data from study in q3 of 2016.  Full Article

BRIEF-Juniper Pharmaceuticals Reports Q1 Earnings Per Share Of $0.06

* JUNIPER PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS